Cell Mol Life Sci:科学家发现新的炎症治疗目标

2012-05-10 Beyond 生物谷

称为初级纤毛的微小细胞器是抗击炎症的关键,伦敦玛丽大学的科学家们发现了一种新的抗击炎症的治疗目标。 相关研究论文发表在Cellular and Molecular Life Sciences杂志上,研究人员发现称为初级纤毛的微小细胞器对调节炎症反应很重要。这一发现可能为百万计患有关节炎的人带来潜在的新的治疗方法。 Martin Knight博士说:“虽然初级纤毛已经发现了有一个多世纪前,但我们

称为初级纤毛的微小细胞器是抗击炎症的关键,伦敦玛丽大学的科学家们发现了一种新的抗击炎症的治疗目标。

相关研究论文发表在Cellular and Molecular Life Sciences杂志上,研究人员发现称为初级纤毛的微小细胞器对调节炎症反应很重要。这一发现可能为百万计患有关节炎的人带来潜在的新的治疗方法。

Martin Knight博士说:“虽然初级纤毛已经发现了有一个多世纪前,但我们才刚刚开始意识到它的重要性,它们在不同的疾病和条件下发挥潜在的治疗益处,可以操纵纤毛结构和功能。

研究人员研究了初级纤毛在炎症反应中的作用。他们把软骨细胞暴露于称为细胞因子特别是白细胞介素1(IL-1)的炎症蛋白环境下,看初级纤毛是否有任何变化。

他说:当我们暴露了细胞于IL-1时,初级纤毛长度在短短的三个小时内增加了50%。

但当我们处理细胞以防止这种纤毛的延伸时。软骨细胞的炎症蛋白大大降低了。研究人员表示:如果我们能更好地操纵初级纤毛,我们就可能会减弱甚至防止发炎。

doi:10.1007/s00018-012-0980-y
PMC:
PMID:

Primary cilia elongation in response to interleukin-1 mediates the inflammatory response

A. K. T. Wann and M. M. Knight

Primary cilia are singular, cytoskeletal organelles present in the majority of mammalian cell types where they function as coordinating centres for mechanotransduction, Wnt and hedgehog signalling. The length of the primary cilium is proposed to modulate cilia function, governed in part by the activity of intraflagellar transport (IFT). In articular cartilage, primary cilia length is increased and hedgehog signaling activated in osteoarthritis (OA). Here, we examine primary cilia length with exposure to the quintessential inflammatory cytokine interleukin-1 (IL-1), which is up-regulated in OA. We then test the hypothesis that the cilium is involved in mediating the downstream inflammatory response. Primary chondrocytes treated with IL-1 exhibited a 50 % increase in cilia length after 3 h exposure. IL-1-induced cilia elongation was also observed in human fibroblasts. In chondrocytes, this elongation occurred via a protein kinase A (PKA)-dependent mechanism. G-protein coupled adenylate cyclase also regulated the length of chondrocyte primary cilia but not downstream of IL-1. Chondrocytes treated with IL-1 exhibit a characteristic increase in the release of the inflammatory chemokines, nitric oxide and prostaglandin E2. However, in cells with a mutation in IFT88 whereby the cilia structure is lost, this response to IL-1 was significantly attenuated and, in the case of nitric oxide, completely abolished. Inhibition of IL-1-induced cilia elongation by PKA inhibition also attenuated the chemokine response. These results suggest that cilia assembly regulates the response to inflammatory cytokines. Therefore, the cilia proteome may provide a novel therapeutic target for the treatment of inflammatory pathologies, including OA.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1802163, encodeId=249c180216350, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu May 17 07:49:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868502, encodeId=4d581868502eb, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Sep 22 09:49:00 CST 2012, time=2012-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005132, encodeId=478f2005132da, content=<a href='/topic/show?id=dcee6e048e4' target=_blank style='color:#2F92EE;'>#炎症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67048, encryptionId=dcee6e048e4, topicName=炎症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Wed Jan 09 04:49:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068402, encodeId=bdbf206840201, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sun Feb 10 20:49:00 CST 2013, time=2013-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958733, encodeId=95361958e33f7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Sep 24 04:49:00 CST 2012, time=2012-09-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1802163, encodeId=249c180216350, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu May 17 07:49:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868502, encodeId=4d581868502eb, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Sep 22 09:49:00 CST 2012, time=2012-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005132, encodeId=478f2005132da, content=<a href='/topic/show?id=dcee6e048e4' target=_blank style='color:#2F92EE;'>#炎症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67048, encryptionId=dcee6e048e4, topicName=炎症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Wed Jan 09 04:49:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068402, encodeId=bdbf206840201, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sun Feb 10 20:49:00 CST 2013, time=2013-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958733, encodeId=95361958e33f7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Sep 24 04:49:00 CST 2012, time=2012-09-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1802163, encodeId=249c180216350, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu May 17 07:49:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868502, encodeId=4d581868502eb, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Sep 22 09:49:00 CST 2012, time=2012-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005132, encodeId=478f2005132da, content=<a href='/topic/show?id=dcee6e048e4' target=_blank style='color:#2F92EE;'>#炎症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67048, encryptionId=dcee6e048e4, topicName=炎症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Wed Jan 09 04:49:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068402, encodeId=bdbf206840201, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sun Feb 10 20:49:00 CST 2013, time=2013-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958733, encodeId=95361958e33f7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Sep 24 04:49:00 CST 2012, time=2012-09-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1802163, encodeId=249c180216350, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu May 17 07:49:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868502, encodeId=4d581868502eb, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Sep 22 09:49:00 CST 2012, time=2012-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005132, encodeId=478f2005132da, content=<a href='/topic/show?id=dcee6e048e4' target=_blank style='color:#2F92EE;'>#炎症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67048, encryptionId=dcee6e048e4, topicName=炎症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Wed Jan 09 04:49:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068402, encodeId=bdbf206840201, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sun Feb 10 20:49:00 CST 2013, time=2013-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958733, encodeId=95361958e33f7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Sep 24 04:49:00 CST 2012, time=2012-09-24, status=1, ipAttribution=)]
    2013-02-10 clmlylxy
  5. [GetPortalCommentsPageByObjectIdResponse(id=1802163, encodeId=249c180216350, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Thu May 17 07:49:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868502, encodeId=4d581868502eb, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Sep 22 09:49:00 CST 2012, time=2012-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005132, encodeId=478f2005132da, content=<a href='/topic/show?id=dcee6e048e4' target=_blank style='color:#2F92EE;'>#炎症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67048, encryptionId=dcee6e048e4, topicName=炎症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b3e473, createdName=pyaili, createdTime=Wed Jan 09 04:49:00 CST 2013, time=2013-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2068402, encodeId=bdbf206840201, content=<a href='/topic/show?id=59371088215' target=_blank style='color:#2F92EE;'>#Life#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10882, encryptionId=59371088215, topicName=Life)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Sun Feb 10 20:49:00 CST 2013, time=2013-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958733, encodeId=95361958e33f7, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Sep 24 04:49:00 CST 2012, time=2012-09-24, status=1, ipAttribution=)]
    2012-09-24 维他命

相关资讯

2010年中国科技论文统计出炉,生物医药领域表现不俗

中国科技信息研究所(下称中信所)12月2日对外发布了2010年中国科技论文(下称国际论文)统计结果。 2010年,我国机构作者为第一作者发表的国际论文共12.15万篇,其中23968篇论文的被引用次数高于学科均线,即其论文发表后的影响超过其所在学科的一般水平,也就是说占我国论文总数的19.7%的论文表现不俗,该比例较2009年的15.5%上升了4.2个百分点。我国表现不俗的论文 81.6%由